In summary, our study demonstrated that in this group of patients with early-stage TNBC enrolled in a single-institution prospective trial and treated with neoadjuvant therapy, PTEN expression was discordant between pretreatment and posttreatment primary tumor samples in 5% (n = 96) of patients and between posttreatment primary tumor and lymph node metastasis in 9% (n = 33) using a stringent cutoff for PTEN IHC scoring. The gene discussed is PTEN; the disease is metastatic malignant neoplasm in the lymph nodes.